Unknown

Dataset Information

0

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.


ABSTRACT: B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28 families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition of T-cell function. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Challenges remain to identify the receptor(s) of B7-H3 and thus better elucidate the role of the B7-H3 pathway in immune responses and tumor evasion. With a preferential expression on tumor cells, B7-H3 is an attractive target for cancer immunotherapy. Based on the clinical success of inhibitory immune checkpoint blockade (CTLA-4, PD-1, and PD-L1), mAbs against B7-H3 appear to be a promising therapeutic strategy worthy of development. An unconventional mAb against B7-H3 with antibody-dependent cell-mediated cytotoxicity is currently being evaluated in a phase I clinical trial and has shown encouraging preliminary results. Additional therapeutic approaches in targeting B7-H3, such as blocking mAbs, bispecific mAbs, chimeric antigen receptor T cells, small-molecule inhibitors, and combination therapies, should be evaluated, as these technologies have already shown positive results in various cancer settings. A better understanding of the B7-H3 pathway in humans will surely help to further optimize associated cancer immunotherapies. Clin Cancer Res; 22(14); 3425-31. ©2016 AACR.

SUBMITTER: Picarda E 

PROVIDER: S-EPMC4947428 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Picarda Elodie E   Ohaegbulam Kim C KC   Zang Xingxing X  

Clinical cancer research : an official journal of the American Association for Cancer Research 20160520 14


B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28 families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition of T-cell function. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Challenges remain to identify the receptor(s) of B7-H3 and thus better elucidate the role of the B7-H3 pathway in immune responses and tumor  ...[more]

Similar Datasets

| S-EPMC8326801 | biostudies-literature
| S-EPMC6069252 | biostudies-literature
| S-EPMC9636568 | biostudies-literature
| S-EPMC10872261 | biostudies-literature
| S-EPMC8297592 | biostudies-literature
| S-EPMC6977319 | biostudies-literature
| S-EPMC9045715 | biostudies-literature
| S-EPMC10802857 | biostudies-literature
| S-EPMC9788608 | biostudies-literature
| S-EPMC8668195 | biostudies-literature